Tadalafil Lilly

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
21-09-2023
Ciri produk Ciri produk (SPC)
21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
07-04-2017

Bahan aktif:

tadalafil

Boleh didapati daripada:

Eli Lilly Nederland B.V.

Kod ATC:

G04BE08

INN (Nama Antarabangsa):

tadalafil

Kumpulan terapeutik:

Urologicals

Kawasan terapeutik:

Erectile Dysfunction

Tanda-tanda terapeutik:

Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.

Ringkasan produk:

Revision: 6

Status kebenaran:

Authorised

Tarikh kebenaran:

2017-03-22

Risalah maklumat

                                61
B. PACKAGE LEAFLET
62
PACKAGE LEAFLET: INFORMATION FOR THE USER
TADALAFIL LILLY 2.5 MG FILM-COATED TABLETS
tadalafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Tadalafil Lilly is and what it is used for
2.
What you need to know before you take Tadalafil Lilly
3.
How to take Tadalafil Lilly
4.
Possible side effects
5
How to store Tadalafil Lilly
6.
Contents of the pack and other information
1.
WHAT TADALAFIL LILLY IS AND WHAT IT IS USED FOR
Tadalafil Lilly is a treatment for adult men with erectile
dysfunction. This is when a man cannot get,
or keep a hard, erect penis suitable for sexual activity. Tadalafil
Lilly has been shown to significantly
improve the ability of obtaining a hard erect penis suitable for
sexual activity.
Tadalafil Lilly contains the active substance tadalafil which belongs
to a group of medicines called
phosphodiesterase type 5 inhibitors. Following sexual stimulation
Tadalafil Lilly works by helping the
blood vessels in your penis to relax, allowing the flow of blood into
your penis. The result of this is
improved erectile function. Tadalafil Lilly will not help you if you
do not have erectile dysfunction.
It is important to note that Tadalafil Lilly does not work if there is
no sexual stimulation. You and your
partner will need to engage in foreplay, just as you would if you were
not taking a medicine for
erectile dysfunction.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TADALAFIL LILLY
DO NOT TAKE TADALAFIL LILLY IF YOU:
-
are allergic to tadalafil or any of the othe
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tadalafil Lilly 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 2.5 mg tadalafil.
Excipient with known effect
Each coated tablet contains 87 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Light orange-yellow and almond shaped tablets of 8.58 mm by 5.23 mm,
marked "C 2 ½" on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult males.
In order for tadalafil to be effective, sexual stimulation is
required.
Tadalafil Lilly is not indicated for use by women.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adult men _
In general, the recommended dose is 10 mg taken prior to anticipated
sexual activity and with or
without food.
In those patients in whom tadalafil 10 mg does not produce an adequate
effect, 20 mg might be tried. It
may be taken at least 30 minutes prior to sexual activity.
The maximum dose frequency is once per day.
Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual
activity and it is not
recommended for continuous daily use.
In patients who anticipate a frequent use of Tadalafil Lilly (i.e., at
least twice weekly) a once daily
regimen with the lowest doses of Tadalafil Lilly might be considered
suitable, based on patient choice
and the physician’s judgement.
In these patients the recommended dose is 5 mg taken once a day at
approximately the same time of
day. The dose may be decreased to 2.5 mg once a day based on
individual tolerability.
The appropriateness of continued use of the daily regimen should be
reassessed periodically.
3
_Special populations _
_Elderly men _
Dose adjustments are not required in elderly patients.
_Men with renal impairment _
Dose adjustments are not required in patients with mild to moderate
renal impairment. For patients
with severe renal impairment 10 mg is the maximum recommended dose.

                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 21-09-2023
Ciri produk Ciri produk Bulgaria 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 07-04-2017
Risalah maklumat Risalah maklumat Sepanyol 21-09-2023
Ciri produk Ciri produk Sepanyol 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 07-04-2017
Risalah maklumat Risalah maklumat Czech 21-09-2023
Ciri produk Ciri produk Czech 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 07-04-2017
Risalah maklumat Risalah maklumat Denmark 21-09-2023
Ciri produk Ciri produk Denmark 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 07-04-2017
Risalah maklumat Risalah maklumat Jerman 21-09-2023
Ciri produk Ciri produk Jerman 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 07-04-2017
Risalah maklumat Risalah maklumat Estonia 21-09-2023
Ciri produk Ciri produk Estonia 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 07-04-2017
Risalah maklumat Risalah maklumat Greek 21-09-2023
Ciri produk Ciri produk Greek 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 07-04-2017
Risalah maklumat Risalah maklumat Perancis 21-09-2023
Ciri produk Ciri produk Perancis 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 07-04-2017
Risalah maklumat Risalah maklumat Itali 21-09-2023
Ciri produk Ciri produk Itali 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 07-04-2017
Risalah maklumat Risalah maklumat Latvia 21-09-2023
Ciri produk Ciri produk Latvia 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 07-04-2017
Risalah maklumat Risalah maklumat Lithuania 21-09-2023
Ciri produk Ciri produk Lithuania 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 07-04-2017
Risalah maklumat Risalah maklumat Hungary 21-09-2023
Ciri produk Ciri produk Hungary 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 07-04-2017
Risalah maklumat Risalah maklumat Malta 21-09-2023
Ciri produk Ciri produk Malta 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 07-04-2017
Risalah maklumat Risalah maklumat Belanda 21-09-2023
Ciri produk Ciri produk Belanda 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 07-04-2017
Risalah maklumat Risalah maklumat Poland 21-09-2023
Ciri produk Ciri produk Poland 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 07-04-2017
Risalah maklumat Risalah maklumat Portugis 21-09-2023
Ciri produk Ciri produk Portugis 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 07-04-2017
Risalah maklumat Risalah maklumat Romania 21-09-2023
Ciri produk Ciri produk Romania 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 07-04-2017
Risalah maklumat Risalah maklumat Slovak 21-09-2023
Ciri produk Ciri produk Slovak 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 07-04-2017
Risalah maklumat Risalah maklumat Slovenia 21-09-2023
Ciri produk Ciri produk Slovenia 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 07-04-2017
Risalah maklumat Risalah maklumat Finland 21-09-2023
Ciri produk Ciri produk Finland 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 07-04-2017
Risalah maklumat Risalah maklumat Sweden 21-09-2023
Ciri produk Ciri produk Sweden 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 07-04-2017
Risalah maklumat Risalah maklumat Norway 21-09-2023
Ciri produk Ciri produk Norway 21-09-2023
Risalah maklumat Risalah maklumat Iceland 21-09-2023
Ciri produk Ciri produk Iceland 21-09-2023
Risalah maklumat Risalah maklumat Croat 21-09-2023
Ciri produk Ciri produk Croat 21-09-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 07-04-2017

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen